<DOC>
	<DOCNO>NCT01473472</DOCNO>
	<brief_summary>This phase III , multi-centre , comparative , double-blind , randomized trial 2 parallel group design evaluate strategy prevention HIV infection include `` demand '' antiretroviral pre-exposure Truvada versus placebo , associate overall prevention ( counsel , condom , sexually transmit disease ( STD ) screening , hepatitis B virus ( HBV ) hepatitis A virus ( HAV ) vaccination post-exposure treatment HIV infection ) men sex men ( MSM ) , expose risk HIV infection . Indeed recent study report high incidence new HIV infection MSM compare general population , new approach prevention HIV infection , therefore , necessary order consider limit current strategy .</brief_summary>
	<brief_title>On Demand Antiretroviral Pre-exposure Prophylaxis HIV Infection Men Who Have Sex With Men</brief_title>
	<detailed_description>The trial take place two phase order ensure general feasibility study : - first enrollment phase least 300 participant ensure possibility recruitment France Canada validate tool put place part trial enroll follow participant - second phase 1600 additional participant . This extension phase start July 2014 . The recruitment suspend follow recommendation Data Safety Monitoring Board ( DSMB ) : placebo arm stop Truvada available participant trial since November 2014 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Age ≥ 18 year old Male ( transgender ) sex men Not infect HIV1 HIV2 Elevated risk HIV contamination : anal sexual relation least 2 different sexual partner within past 6 month without systematic use condom Satisfactory kidney function clearance 60 mL/min ( Cockcroft formula ) Alanine aminotransferase ( ALT ) &lt; 2.5 Upper Limit Normal ( ULN ) , Neutrophil granulocytes ≥ 1 000/mm3 , haemoglobin ≥ 10 g/dL , platelet ≥ 150 000/mm3 Negative HBs antigen negative hepatitis C virus ( HCV ) serology ( negative HCV PCR positive serology ) Agrees contact personally , possible telephone , short message system ( SMS ) email Agrees constraint impose trial ( visit every 2 month ) Subjects enrolled beneficiary Social Security program ( State Medical Aid Aide médicale de l'Etat ( AME ) Social Security program ) . Signature informed consent form . Subject stable exclusive relationship person Systematic use condom sexual relation Expected go abroad 3 consecutive month move expect city study conduct . Presence significant glycosuria proteinuria &gt; 1+ urine dipstick , absence infection . Presence significant haematuria leukocyturia &gt; 2+ urine dipstick , absence infection . History chronic kidney disease , osteoporosis , osteopaenia History pathological bone fracture relate trauma Treatment Interferon , Interleukin , antiretrovirals Treatment could inhibit compete tubular secretion antiretrovirals Treatment undergo investigation Intravenous toxicomania Subject currently receive go receive potentially nephrotoxic treatment ( longterm antiinflammatory ) Gastrointestinal disease ( chronic nausea vomit ) disrupt absorption treatment Positive HBs antigen Positive HCV serology positive HCV PCR Lifethreatening disease ( lymphoma ) serious disease ( cardiovascular , renal , pulmonary , unstable diabetes ) could require treatment could disrupt adherence treatment Subject potentially noncompliant .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prophylaxis</keyword>
	<keyword>HIV infection</keyword>
	<keyword>tenofovir</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>men sex men</keyword>
</DOC>